Submitting to Nature Medicine.

01 About Nature Medicine

Nature Medicine is a flagship journal published by Nature Portfolio, covering research at the intersection of basic science and clinical application. The journal's content spans medicine broadly, with strong representation in immunology and microbiology, biochemistry, genetics and molecular biology, physiology, reproductive medicine, public health, and molecular biology. With 16,324 works published and a cumulative cited-by count of 2,539,604, Nature Medicine occupies a central position in the biomedical literature. Its h-index of 761 and two-year mean citedness of approximately 27.4 reflect the sustained influence its publications have across the research community.

The journal attracts work that bridges laboratory discovery and patient-relevant outcomes: translational studies, large-scale epidemiological analyses, clinical trials, and increasingly, computational and AI-driven approaches to medicine. Readers include clinicians, biomedical researchers, public health scientists, and immunologists. If you are preparing a manuscript for Nature Medicine, you are competing for space in one of the most selective venues in biomedicine, and the rigor of your methodology and reporting will be scrutinized accordingly.

02 Reporting Standards

Biomedical and clinical research is governed by a set of well-established reporting frameworks designed to ensure that published studies are transparent, reproducible, and interpretable. Authors targeting journals in medicine and immunology, the primary fields covered by Nature Medicine, should be thoroughly familiar with these standards before submitting.

For randomized controlled trials, CONSORT (Consolidated Standards of Reporting Trials) provides a checklist and flow diagram that guide authors through the minimum information required for a trial to be evaluated critically. For observational studies (cohort, case-control, and cross-sectional designs), STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) serves the equivalent function. Systematic reviews and meta-analyses should follow PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses), which requires a detailed flow diagram of study selection and explicit documentation of search strategies. For studies involving animal models, ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines apply.

Adherence to these frameworks does not merely satisfy editorial formality. Reviewers use them as a diagnostic tool: a missing CONSORT flow diagram or an undocumented randomization procedure signals to a reviewer that the study may have methodological gaps, whether or not those gaps actually exist. Proactively aligning your manuscript with the appropriate reporting standard before submission reduces the likelihood of a rejection on procedural grounds and demonstrates methodological literacy to editors and reviewers alike.

03 Common Methodology Concerns

Manuscripts submitted to high-impact medical and immunology journals are routinely scrutinized for a cluster of methodological issues that, if unaddressed, can result in rejection or major revision requests regardless of the scientific novelty of the findings.

On the clinical and epidemiological side, reviewers consistently flag inadequate sample size justification. A power analysis (specifying the expected effect size, desired power, and significance threshold) should appear in the methods section, not as an afterthought in a response to reviewers. Closely related is the handling of missing data: authors should explicitly state whether missing data were handled through imputation, complete-case analysis, or another approach, and justify that choice. For randomized trials, intention-to-treat analysis is the expected default, and deviations from it require clear explanation. Blinding, randomization, and allocation concealment must each be described with enough specificity that a reader can assess the risk of bias. Vague phrases like "patients were randomized" without describing the mechanism are routinely flagged. Finally, manuscripts reporting clinical or epidemiological data are expected to demonstrate adherence to CONSORT, STROBE, or PRISMA as appropriate to the study design.

On the immunology side, flow cytometry is a foundational technique, and reviewers expect gating strategies to be documented, typically in supplementary figures, so that the analysis can be evaluated and reproduced. Similarly, antibody reagents must be reported with clone numbers and evidence of titration validation. Undocumented antibody usage is a common source of irreproducibility and is treated seriously by reviewers in this field. Addressing these concerns before submission, rather than in revision, positions your manuscript more favorably from the outset.

04 Recent Representative Work

The breadth of recent publications in Nature Medicine reflects the journal's range across translational medicine, computational approaches, environmental health, and global epidemiology. The following papers, all published in 2025, illustrate the scope of work currently appearing in the journal:

05 Pre-Submission Checklist

06 How PeerPanel Reviews Your Manuscript

Before your manuscript reaches Nature Medicine's editorial team, PeerPanel runs it past five specialist agents, each focused on a distinct dimension of manuscript quality.

07 Where to Find Author Guidelines

Before submitting to Nature Medicine, consult the journal's official author guidelines directly on the Nature Medicine homepage. The official instructions cover word limits, figure specifications, reference formatting, required statements, and submission procedures. These details change periodically, and PeerPanel does not reproduce or summarize them. Reading the journal's own instructions is a non-negotiable step in the submission process. No third-party resource, including this page, substitutes for it.